HealthspanX Evidence Center
Nicotinamide Mononucleotide (NMN) Research
Human studies
-
Tier 2
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
- Analysis in review
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
Full analysis will appear here once it clears review.
-
Tier 4
Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men
First-in-human safety study of single oral NMN doses (100, 250, 500 mg) in ten Japanese men. Well tolerated at all doses; downstream metabolites 2Py and 4Py rose dose-dependently.
-
Tier 2
MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults
Two-week RCT in 32 adults aged 55–80 showing pharmaceutical-grade NMN (MIB-626) at 1,000 mg once or twice daily raised blood NAD⁺ substantially versus placebo with a safety profile matching placebo.
-
Tier 2
Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study
12-week RCT (n=108) in Japanese adults aged ≥65 comparing morning vs evening 250 mg NMN. Evening dosing improved lower-limb function (5-STS) and reduced drowsiness with the largest effect sizes.
-
Tier 2
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
12-week randomized trial of 250 mg/day oral NMN in 34 healthy adults aged 40–59, examining arterial stiffness and NAD metabolism markers.
Reviews and perspectives
No records are currently classified under reviews and perspectives.
Preclinical and mechanistic research
-
Tier 3
A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration
Foundational preclinical paper establishing that NMN accumulation — not NAD depletion alone — is what triggers axon degeneration after nerve injury in mice and zebrafish.
-
Tier 3
A conformation-specific nanobody targeting the nicotinamide mononucleotide-activated state of SARM1
Cryo-EM structural study resolving how NMN activates SARM1, the enzyme that drives axon degeneration when nerve injury depletes NMNAT2. Uses a nanobody to trap the active state.